Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and other conditions involving neurodegeneration. The Company's drug, davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA).


GREY:NPCUF - Post by User

Post by kiskadogon Nov 25, 2015 11:35am
124 Views
Post# 24324134

BUYS better than SELLS

BUYS better than SELLS
Always good to see NPC insiders BUYING vs SELLING.

As of 11:59pm ET November 24th, 2015 Filing
Date Transaction
Date Insider Name Ownership
Type Securities Nature of transaction Volume or Value Price Nov 13/15 Nov 11/15 Tremblay, Denis Direct Ownership Common Shares 10 - Acquisition in the public market 26,000 $0.750
Nov 13/15 Nov 10/15 Filion, Yves Direct Ownership Common Shares 10 - Acquisition in the public market 40,000 $0.750
Nov 11/15 Nov 10/15 Rochette, Jean Direct Ownership Common Shares 10 - Acquisition in the public market 15,000 $0.742
Nov 11/15 Nov 10/15 Rochette, Jean Direct Ownership Common Shares 10 - Acquisition in the public market 16,000 $0.745
Nov 11/15 Nov 10/15 Reny, Luc Direct Ownership Common Shares 10 - Acquisition in the public market 30,000 $0.741 - See more at: https://www.canadianinsider.com/company?menu_tickersearch=NPC%20%7C%20NAPEC#sthash.scyezcTN.dpuf

https://www.canadianinsider.com/company?menu_tickersearch=NPC%20|%20NAPEC

As of 11:59pm ET November 24th, 2015 Filing
Date Transaction
Date Insider Name Ownership
Type Securities Nature of transaction Volume or Value Price Nov 13/15 Nov 11/15 Tremblay, Denis Direct Ownership Common Shares 10 - Acquisition in the public market 26,000 $0.750
Nov 13/15 Nov 10/15 Filion, Yves Direct Ownership Common Shares 10 - Acquisition in the public market 40,000 $0.750
Nov 11/15 Nov 10/15 Rochette, Jean Direct Ownership Common Shares 10 - Acquisition in the public market 15,000 $0.742
Nov 11/15 Nov 10/15 Rochette, Jean Direct Ownership Common Shares 10 - Acquisition in the public market 16,000 $0.745
Nov 11/15 Nov 10/15 Reny, Luc Direct Ownership Common Shares 10 - Acquisition in the public market 30,000 $0.741 - See more at: https://www.canadianinsider.com/company?menu_tickersearch=NPC%20%7C%20NAPEC#sthash.scyezcTN.dpuf
<< Previous
Bullboard Posts
Next >>